Company & Sponsor Intelligence

Chelsea Therapeutics

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed3

Countries2

Therapeutic footprint

movement_disorderspain_neuropathyparkinsons

Indexed studies

NCT01323374Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia
pain_neuropathy · United KingdomPHASE2

NCT01176240A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
parkinsons · United StatesPHASE3

NCT00633880Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
movement_disorders · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →